Feature

Servier and French drug safety agency found guilty on diet drug


 

Mediator should never have been authorized for use

In terms of the fraud charges, the prosecutor estimated that the losses incurred by the primary health insurance industry were in the region of several hundred million euros.

She argued that Mediator should never have been reimbursed, as “it should never have benefited from market authorization, which it received solely due to the fraudulent actions of the company.”

But because of the statute of limitations, this argument was not heard, explained Dr. Frachon, “and the same is true of conflicts of interest, where limitations led to them being discharged.

“We understand the legal difficulties, but it’s a shame in terms of the signal sent.”

“I hope the medical world will learn the lesson and not continue with ‘business as usual’ with people who are delinquents. I think it will be essential to restore public confidence,” concluded Dr. Frachon.

No conflicts of interest or funding were declared.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Thirteen percent of patients with type 2 diabetes have major ECG abnormalities
Federal Practitioner
Big data ‘clinch’ link between high glycemic index diets and CVD
Federal Practitioner
Heart failure redefined with new classifications, staging
Federal Practitioner
Semaglutide for meaningful weight loss in obesity and diabetes?
Federal Practitioner
Clinical Impact of Initiation of U-500 Insulin vs Continuation of U-100 Insulin in Subjects With Diabetes
Federal Practitioner
‘Major update’ of BP guidance for kidney disease; treat to 120 mm Hg
Federal Practitioner
High obesity rates in Southern states magnify COVID threats
Federal Practitioner
Diabetes prevention moves toward reality as studies published
Federal Practitioner
Women with PCOS at increased risk for COVID-19
Federal Practitioner
Use of complimentary and alternative medicine common in diabetes patients
Federal Practitioner